Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design
- 16 January 2009
- journal article
- review article
- Published by Springer Nature in Hypertension Research
- Vol. 32 (2), 109-114
- https://doi.org/10.1038/hr.2008.26
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular RisksHypertension, 2008
- Idraparinux versus Standard Therapy for Venous Thromboembolic DiseaseNew England Journal of Medicine, 2007
- RETRACTED: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality studyThe Lancet, 2007
- Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trialThe Lancet, 2006
- Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary PreventionStroke, 2005
- The statin warsThe Lancet, 2003
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm HgJAMA, 1967